A：The company uses non GAAP and pro forma financial measures to establish operational goals and review operational performance. These measures are believed to assist investors in analyzing the underlying trends in the company's business over time.

A：The company's strategic approach to transform itself into a fast-growing, profitable company by bringing innovation to large global markets has been successful. This is evidenced by the medtech segment's performance and the company's overall execution across its platforms.

A：The medtech segment's revenue was 47% of total revenue in fiscal 2026, up from roughly 22% at the end of fiscal 2020. Over the past six years, this business has grown at a compound annual rate of approximately 24%.

A：Aeon is a product that has delivered its 20th consecutive quarter of double-digit year-over-year growth, continuing to take share across all sites of care. The Arion platform remains a strong performer for the company.

A：The Mechanical Mbox Tomy portfolio grew double digits during the year, driven by strong performance with alpha vac and angio vacu. Upcoming growth catalysts include the alpha return blood management system with IDE approval and an active pivotal trial, and the angio back right heart program.

A：The nanoliter product had an exceptional fourth quarter in the U.S., driven by physician interest and procedure volumes. This resulted in record procedures during the quarter and the achievement is attributed to deliberate work on the fundamentals that drive the business.

A：The med device business is crucial as it plays an essential role in delivering steady, profitable growth from a portfolio of sticky market-leading products. It contributes to the company's cash generation profile and earnings foundation, allowing investment in higher growth medical technology platforms.

A：The key theme of fiscal 2026 is the consistent delivery of above-market profitable growth, market share gains, and profitability expansion while generating positive cash flow. The company continues to invest in the clinical data behind its platforms.

A：The company is in the process of a leadership transition, with a search being conducted by the board to identify a new CEO. The current CEO intends to retire and will continue to lead the team alongside the CFO until a successor is in place, expected during the first half of fiscal 2023.

A：The Medtech platforms comprised 40% of the total revenue compared to 45% a year ago.

A：The Ariane platform contributed $17.8 million to the revenue, growing 14.4% compared to last year.

A：The total revenue grew by 35.2% to $11.8 million. Disposables grew by 47% and capital sales grew by 132.5%. Capital sales are always lumpy, so a continued growth at the same rate is not expected.

A：The Med device segment's revenue increased year over year with $100.0 million in revenue in the fourth quarter.

A：Total operating expenses for the fourth quarter were $57 million, representing 66% of sales compared to $48 million or 60% of sales last year.

A：Revenue increased 9.4% to $320.2 million, primarily driven by growth across the Medtech segment. Medtech revenue grew 17.7%, anco mbokomu revenue (includes angio econ and alphabet) increased 13.4%, and angio backcloth grew 2.1% year over year.

A：In fiscal 2026, Med device revenue was $170.2 million, an increase of 2.5%. The gross margin for fiscal year 2026 was 54.6%, a 70 basis point increase from the prior year. Total operating expenses were $214.8 million or 67% of sales compared to $197.8 million, or 68% of sales a year ago. The adjusted net loss for fiscal year 2026 was $10 million, or an adjusted loss per share of 24 cents, compared to an adjusted net loss of $10.2 million or an adjusted loss per share of 25 cents last year. On a GAAP basis, the total net loss for the full year was $36.7 million, or a loss per share of 88 cents, compared to a net loss of $13.7 million or a loss per share of 33 cents a year ago. Adjusted EBITDA for the full fiscal year 2026 was $13.2 million compared to $7.6 million in fiscal year 2025.

A：The expected gross margin for fiscal 2027 is in the range of 54% to 55%, and the expected adjusted EBITDA is in the range of 13 to 16 million.

A：The company anticipates that the impact from tariffs will be broadly similar to fiscal 2026 based on its current view of the tariff situation, which remains dynamic and subject to change.

A：The results from the investigator initiated study at the AUA Conference in May showed a 100% negative rate at 12 months, a 90% reduction in P from baseline at 3 months, and a significant improvement in quality of life following treatment with no grade 3 or higher adverse events.

A：The company, Angiodynamics, is built to be a consistent performer and is well-aware of the broader environment. They are positioned in growing markets, have a clean, debt-free balance sheet, and intend to continue investing for the future while improving profitability.

A：The company is excited about the new LCD ruling from Palmetto and the positive reimbursement decision. They expect it to be an important element for driving adoption and believe the results are the early stages of benefits from these decisions, with work remaining to ensure consistent reimbursement across the country.

A：The potential market size for BPH relative to prostate cancer is being cautious and learning more from physicians. They have received positive feedback from users and plan to be transparent with the findings once the study is complete. There is significant interest in the product and space.

A：The company is looking into the causes for the quarter-over-quarter declines in the mechanical thrombectomy business but had goals to do more than the single-digit growth they achieved for the year. They are yet to provide additional details on the causes.

A：To increase market share in the competitive Tervis market, the company is focusing on internal improvements such as changes in the commercial approach, new leadership structure, and training the salesforce to enhance effectiveness. These changes are expected to make the company a growth driver in the near future.

A：The company expects Q4 to be the highest in terms of both revenue and cash generation, with Q3 being a sequential step up from Q1 and Q2, and Q1 being a slight step down from Q2. Q4 is also typically the highest utilization of cash quarter.

A：The company anticipates that the quarterly trends seen in the middle of the year, such as Q2 and Q3, will be mitigated in the upcoming year as the company grows. Despite potential lumpiness due to growth, the overall cadence is expected to follow the same pattern based on the company's fiscal structure.

A：The guidance suggests that while there is some seasonality that affects the disposal revenue from NanoKnife, the increase in adoption by urologists indicates a higher baseline for nanobes. The expected disposal revenue will be influenced by both the ongoing adoption trends and the seasonality of the business.

A：The company has assessed its performance in the field, analyzed the competitive market, and made changes to its leadership structure and hiring new personnel as part of its commercial strategy. The exact number of new representatives hired was not specified in the transcript.

A：In the mechanical thrombectomy business, the company does not observe significant pricing pressure. Boston Scientific and Medtronic are identified as competitors in the cardiovascular categories, but the company's product is considered very good, and pricing has not been an issue in the market due to the value provided to providers.

A：The company is experiencing market share growth due to having the best product in the market, Ariane, which is effective both above and below the knee. Additionally, about 10% of the company's procedures are instant renos, a feature that other products cannot match. The company also boasts a strong selling and clinical team that supports customers, leading to continuous wins in acquiring new customers and increasing their procedure volume with the Aion device.

A：The decision by Medicare to cover the company's product is significant because it demonstrates the safety and effectiveness of the device, allowing patients to get treated and doctors and hospitals to be paid. This coverage opens opportunities for urologists to try the product and treat their patients, supported by positive economic outcomes.

A：The company plans to manage its investment in the clinical pipeline and research and development by targeting approximately 10% of sales as the ongoing annual investment for these areas. The guidance provided indicates that there won't be a significantly higher investment in 2027, particularly in research and development and clinical spend, beyond the already expected 10%. However, the company will continue to invest in all growth drivers within Medtech to sustain above-market growth rates.